2025 Texas sessionsRegular and both called sessions have ended. This index covers House and Senate bills, not resolutions. Statuses come from official reports.

2025 · Regular session · House bill

HB4638

HB4638 keeps the Texas Pharmaceutical Initiative's governing law in place until September 1, 2027, instead of letting it expire September 1, 2025.

Read bill highlights ↓

Official caption: Relating to the Texas Pharmaceutical Initiative.

Signed by governorSource-checked explanation published

Official report lists House author(s): Bonnen. This does not identify sponsors or amendment drafters.

Report an error ↗

Bill explanation published · Version and amendment review scope is stated below · Individual amendment records may not be separately annotated.

Bill highlights

Selected points from the published explanation. Follow each point to its source-linked context; conditions and limits may matter.

HB4638 keeps the Texas Pharmaceutical Initiative's governing law in place until September 1, 2027, instead of letting it expire September 1, 2025.
The initiative already existed to pursue cost-effective prescription-drug and medical-supply access for specified groups: public higher-education employees, dependents and retirees; ERS and TRS members; people confined by TDCJ or TJJD; and individuals served by health-and-human-services programs.
The law expands the governor-appointed board from three to five members and establishes staggered six-year terms, with vacancies filled for the remainder of a term.
The board must submit a business plan to the governor, legislature and Legislative Budget Board by June 1 of every even-numbered year, replacing the old one-time October 1, 2024 deadline.
Existing planning subjects remain, including pharmacy-benefit management, drug distribution, generic-drug and biological-product manufacturing, advanced pharmaceutical services, conflicts of interest, participation conditions, potential savings and required resources.

Read the full explanation ↓

What does it do?

HB4638 keeps the Texas Pharmaceutical Initiative’s governing law in place until September 1, 2027, instead of letting it expire September 1, 2025. The bill was signed June 20, 2025, and took effect September 1, 2025. It does not make the initiative permanent.

The initiative already existed to pursue cost-effective prescription-drug and medical-supply access for specified groups: public higher-education employees, dependents and retirees; ERS and TRS members; people confined by TDCJ or TJJD; and individuals served by health-and-human-services programs. HB4638 does not create a universal drug benefit for all Texans or guarantee a particular discount. Existing scope, Government Code Section 2177.002.

The law expands the governor-appointed board from three to five members and establishes staggered six-year terms, with vacancies filled for the remainder of a term. Initial appointments are staggered: two expire February 1, 2027; two February 1, 2029; and one February 1, 2031. Those later appointment dates do not override the chapter’s September 2027 expiration. Further legislative action would be needed to change that statutory sunset.

The board must submit a business plan to the governor, legislature and Legislative Budget Board by June 1 of every even-numbered year, replacing the old one-time October 1, 2024 deadline. The plan must now also recommend best practices and pharmacy-benefit cost savings using program-utilization information.

Existing planning subjects remain, including pharmacy-benefit management, drug distribution, generic-drug and biological-product manufacturing, advanced pharmaceutical services, conflicts of interest, participation conditions, potential savings and required resources. Requiring a plan for these activities is not proof that every service is operating or that projected savings have occurred. The board remains administratively attached to HHSC; existing qualification and conflict-of-interest requirements are not repealed.

What changed along the way?

The introduced bill would have repealed the expiration provision altogether. The House substitute instead proposed a September 1, 2031 expiration and added the utilization-based best-practices and savings recommendation. The House-passed and Senate committee versions matched that substitute.

The sole indexed floor amendment, Kolkhorst’s Senate amendment 1, changed 2031 to 2027. It was adopted May 27, and the House concurred May 29. The final law therefore grants a two-year extension, not permanence or the longer House-proposed extension. The amendment did not change the separately listed initial board-term dates.

The history, text index, amendment index and Senate packet document the proposal-to-law distinction.

For the full amendment record, open the official amendment index.

Official bill versions

Compare the published text versions in the official text index. A change is not attributed to a specific amendment here without a verified record.

Who could benefit—and who could bear the costs?

Covered public programs and their participants retain the opportunity to pursue coordinated pharmaceutical purchasing and other initiative activities. A larger board and recurring business plans can support oversight, but also require administrative work. Any lower drug costs depend on implementation, contracts and funding—not merely passage of this bill.

The final fiscal note anticipated no significant state or local fiscal implication, assuming state costs could be absorbed within existing resources. It did not promise or quantify pharmaceutical savings. The act includes no new appropriation.

Official sources

Catalog report retrieved 2026-10-25. Check the official record for corrections or later changes.